Volume 19 Supplement 2

Eighth International Symposium on Intensive Care and Emergency Medicine for Latin America

Open Access

Impact of chest pain protocol in the use of fibrinolytic therapy in a private hospital network with access to telemedicine in a middle income country

  • Pedro Gabriel MB Silva1,
  • Antonio Baruzzi1,
  • Giuliano Generoso1,
  • Henrique Ribeiro1,
  • Jose Carlos Teixeira1,
  • Marcelo Jamus1,
  • Mariana Y Okada1,
  • Sheila Simoes1,
  • Thiago A Macedo1 and
  • Valter Furlan1
Critical Care201519(Suppl 2):P7

https://doi.org/10.1186/cc14663

Published: 28 September 2015

Introduction

Brazilian registries [1] have shown that there is a gap between evidence-based therapies and the real treatment provided to patients with myocardial infarction. A chest pain protocol was implemented in a private hospital group in 2012 aiming at standardized optimal care for these patients.

Objective

To evaluate the hypothesis of improving the use of reperfusion therapy and benefit in clinical outcomes in patients with STEMI after 2 years of implementation of the protocol in a large chest pain network.

Methods

In 2012, physicians and nurses from 22 emergencies were trained to comply with a chest pain protocol and were provided access to telemedicine with a reference cardiologist available 24 hours a day, 7 days a week, for clinical discussion. All cases of ST segment elevation myocardial infarction (STEMI) were transferred to a reference hospital and the use of fibrinolytics before transfer (pharmacoinvasive strategy) was recommended. Data of STEMI patients transferred in 2011 (before protocol and telemedicine) were compared with the patients treated in 2013/14 (after implementation). A maximum limit of significance of 5% was defined for the chance of type I error (p < 0.05 was considered statistically significant).

Results

The number of patients transferred to the reference hospital was 113 (2011), 140 (2013) and 123 (2014). Fibrinolytic therapy was used in 43 patients (38%) in 2011 and in 147 cases (55.8%) in 2013/14 (p = 0.002). The mortality rates of transferred STEMI cases were 8% in 2011 (nine cases) and 3% (eight cases) in 2013/14 (p = 0.06) with an observed/expected mortality by Grace score of 1.11 (95% CI, 0.39-1.83) in 2011 and 0.68 (95% CI, 0.21-1.15) in 2013/14. Along the years of 2011, 2012 and 2013, two patients treated with fibrinolytics died during the hospital stay (1.05%), whereas hospital mortality was 8.06% among those not treated with thrombolysis (p < 0.001). The patients that received reperfusion therapy in the first hospital used telemedicine more frequently (63.3% versus 42.2%; p = 0.001). See Table 1.
Table 1

Baseline characteristics.

 

2011 (n= 113)

2013/14 (n= 263)

pvalue

Mean age (years)

59.6 (±13)

58.7 (±11)

0.49

Male

70%

74%

0.47

Hypertension

62%

64%

0.81

Diabetes

26%

29%

0.61

Previous PCI or CABG

14.2%

10.6%

0.43

Previous myocardial infarction

7.1%

5.7%

0.78

Mean Grace risk score (mortality)

7.2%

4.4%

0.5

PCI percutaneous coronary intervention, CABG coronary artery bypass graft.

Conclusion

Two years after implementation of a chest pain protocol in a private emergency network, there was significant increase in the use of reperfusion therapy probably explained by a more frequent use of telemedicine in the group treated with reperfusion therapy.

Authors’ Affiliations

(1)
Hospital Totalcor, Cerqueira Cesar, São Paulo

References

  1. Nicolau JC, Franken M, Lotufo PA, Carvalho AC, Marin Neto JA, Lima FG, et al: Utilização de terapêuticas comprovadamente úteis no tratamento da coronariopatia aguda:comparação entre diferentes regiões brasileiras. Análise do Registro Brasileiro de Síndromes Coronarianas Agudas (BRACE--Brazilian Registry on Acute Coronary Syndromes). Arq Bras Cardiol. 2012, 98 (4): 282-289. 10.1590/S0066-782X2012000400001.View ArticlePubMedGoogle Scholar

Copyright

© M.B. Silva et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement